How has Charles River Laboratories's RMS — operating income (loss) changed year-over-year?

Charles River Laboratories's RMS — operating income (loss) increased by 1.4% year-over-year, from $35.79M to $36.28M.

What does RMS — operating income (loss) mean?

Measures the profitability of the Research Models and Services segment by subtracting operating expenses from total segment revenue. It provides a clear view of the segment's ability to generate profit from its core business activities before interest and taxes. This is the primary metric for assessing the segment's operational health.

Charles River Laboratories (CRL) RMS — Operating Income (Loss)

Screener

Other segment segments

DSA

$124.4M+1.3%

Manufacturing

$65.61M+444%

Similar metrics at other companies

DRSIMS — Operating Income (Loss)

$37M+8.8%

METRIS — Operating Income (Loss)

$377M+1.9%

PSAAncillary operations — Operating Income (Loss)

$56.65M+15.3%

NINIPSCO Operations — Operating Income (Loss)

$120.4M-10.1%

TRCRanch operations — Operating Income (Loss)

-$93K+63.1%

CSXRail Operations — Operating Income (Loss)

$1.49B+16.9%

Other financials

Income statement

See full

Revenue$1.0B-2.7%

Gross profit$349.0M-3.5%

Operating income$119.9M+19.7%

Net income-$1.5M-103%

EPS (diluted)-$0.03-103%

Balance sheet

See full

Cash & equivalents$240.6M+30.2%

Total debt$3.0B+8.1%

Total equity$2.8B-15.3%

Total assets$7.5B-0.4%

Cash flow

See full

Operating cash flow$179.7M-12.2%

CapEx$31.1M-11.9%

Free cash flow$148.6M-12.2%

Valuation

See full

Market cap$12.56B+70.1%

Enterprise value$15.36B+53.4%

P/S3.1×+1.3×

Profitability

See full

Gross margin84.7%—

Operating margin13%-2.4pp

Net margin-6%—

FCF margin9.3%-5.1pp

Returns & leverage

See full

Return on equity-7.7%—

Debt / equity1.1×+0.2×

Current ratio1.3×0.0×

Where this comes from

Reported directly by Charles River Laboratories in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Charles River Laboratories’s 10-Q, filed August 5, 2026.

Filed: Aug 5, 2026, 9:21 AM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001100682-26-000118

Line item	Three Months Ended / June 27, 2026	Three Months Ended / June 28, 2025	Six Months Ended / June 27, 2026	Six Months Ended / June 28, 2025
Cost of products sold (excluding amortization of intangible assets)	88,697	90,192	180,956	179,200
Selling, general and administrative	228,897	191,549	388,319	369,348
Amortization of intangible assets	14,589	65,384	29,934	130,648
Operating income	119,888	100,134	239,785	174,803
Other income (expense)
Interest income	1,032	1,097	2,065	2,501
Interest expense	(30,340)	(29,967)	(57,082)	(57,851)
Other (expense) income, net	(37,410)	154	(161,540)	(12,057)

Item 1. Financial Statements

FAQ

What is Charles River Laboratories's RMS — operating income (loss)?: Charles River Laboratories (CRL) reported RMS — operating income (loss) of $36.28M in Q2 2026.
How has Charles River Laboratories's RMS — operating income (loss) changed year-over-year?: Charles River Laboratories's RMS — operating income (loss) increased by 1.4% year-over-year, from $35.79M to $36.28M.
What does RMS — operating income (loss) mean?: Measures the profitability of the Research Models and Services segment by subtracting operating expenses from total segment revenue. It provides a clear view of the segment's ability to generate profit from its core business activities before interest and taxes. This is the primary metric for assessing the segment's operational health.